Jiahuang Lin, PhD

MSD, China
N/A, Beijing, China

Disclosure information not submitted.

Presentation(s):

• 133 - Clesrovimab Efficacy through 6 Months during a Time of Changing SARS-CoV-2 Nonpharmaceutical Interventions (NPIs): Subgroup Analysis of the China Cohort in the Phase 2b/3 CLEVER Trial

  Monday, October 20, 2025
  12:25 PM - 12:30 PM US ET